C9038 HCPCS Level II code: Injection, mogamulizumab-kpkc, 1 mg
CMS terminated C9038: its last date of service was Sep 30, 2019. It stays here for looking up older claims; newer services need a current code.
Official description
C9038Injection, mogamulizumab-kpkc, 1 mg
Short description: Inj mogamulizumab-kpkc
HCPCS · United States
Medicare details
The indicators CMS publishes with C9038 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services; Ambulatory surgical center (facility usage for surgical services)
- BETOS category
- Other drugs
- Coverage statute
- 1833(t)
- Added
- Jan 1, 2019
- Terminated after
- Sep 30, 2019
Where C9038 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9038Injection, mogamulizumab-kpkc, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9038 still valid?
No. CMS terminated C9038; its last date of service was Sep 30, 2019. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9038?
CMS lists C9038’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9038
All C codesC9032Injection, voretigene neparvovec-rzyl, 1 billion vector genomeC9033Injection, fosnetupitant 235 mg and palonosetron 0.25 mgC9034Injection, dexamethasone 9%, intraocular, 1 mcgC9035Injection, aripiprazole lauroxil (aristada initio), 1 mgC9036Injection, patisiran, 0.1 mgC9037Injection, risperidone (perseris), 0.5 mgC9039Injection, plazomicin, 5 mgC9040Injection, fremanezumab-vfrm, 1mgC9041Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mgC9042Injection, bendamustine hcl (belrapzo), 1 mgC9043Injection, levoleucovorin, 1 mgC9044Injection, cemiplimab-rwlc, 1 mg